On the role of pentoxifylline versus other TNF alpha inhibitors in the prevention of hepatorenal syndrome

Medical Hypotheses

Volumn 79, Issue 4, 2012, Pages 552-553

  Riaz, Haris ^a   Tahir, Faryal ^a   Munir, Muhammad Bilal ^b,c  

^a DOW UNIVERSITY OF HEALTH SCIENCES   (Pakistan)

^b Och Spine at New York Presbyterian Hospitals   (United States)

^c UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PENTOXIFYLLINE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ALCOHOL LIVER DISEASE; DISEASE COURSE; DRUG EFFICACY; HEPATITIS C; HEPATORENAL SYNDROME; HUMAN; INFECTION RISK; LETTER; LIVER CIRRHOSIS; PROPHYLAXIS;

EID: 84865982311     PISSN: 03069877     EISSN: 15322777     Source Type: Journal    
DOI: 10.1016/j.mehy.2012.07.007     Document Type: Letter

References (6)

1. Tahir F., Riaz H., Rehman A., Munir M.B. Potential role of TNF alpha blockers in delaying the progression of hepato-renal syndrome. Med Hypotheses 2012, 78(2):6-225.
2. Keane J., Gershon S., Wise R.P., Mirabile-Levens E., Kasznica J., Schwieterman W.D., et al. Tuberculosis associated with infliximab a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001, 345(15):104-1098.
3. Grijalva C.G., Chen L., Delzell E., Baddley J.W., Beukelman T., Winthrop K.L., et al. Initiation of tumor necrosis factor-α antagonists and the risk of hospitalization for infection in patients with autoimmune diseases. JAMA 2011, 306(21):9-2331.
4. Viganò M., Degasperi E., Aghemo A., Lampertico P., Colombo M. Anti-TNF drugs in patients with hepatitis B or C virus infection: safety and clinical management. Expert Opin Biol Ther 2012, 12(2):193-207.
5. Li W., Zheng L., Sheng C., Cheng X., Qing L., Qu S. Systematic review on the treatment of pentoxifylline in patients with non-alcoholic fatty liver disease. Lipids Health Dis 2011, 10:49.
6. González-Espinoza L., Rojas-Campos E., Medina-Pérez M., Peña-Quintero P., Gómez-Navarro B., Cueto-Manzano A.M. Pentoxifylline decreases serum levels of tumor necrosis factor alpha, interleukin 6 and C-reactive protein in hemodialysis patients: results of a randomized double-blind, controlled clinical trial. Nephrol Dial Transplant 2011, [Epub ahead of print].